drug
RIVAROXABAN
Marketedupdated 3mo agoby Reddy US Therapeutics Inc
Approvedannual revenue · 2024–2024peak $2.1B
community read0 votes
🐶 often sniffed alongside
top 4indications
investigational
Atrial Fibrillation
all catalysts(4)
Trials studying RIVAROXABAN
- phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- N/ADEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
- —A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- —An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
- N/APill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation
- phase1A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
- —An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
- phase3Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 17, 2034
~7.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Aug 17, 2034patentUS 9539218*PED
- Aug 17, 2034patentUS 9539218*PED
- Aug 17, 2034patentUS 9539218*PED
- Feb 17, 2034method-of-use (U-3289)US 9539218
- Feb 17, 2034method-of-use (U-3285)US 9539218
- Feb 17, 2034method-of-use (U-3288)US 9539218
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that